Drug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies

Stock News

08/12

Shanghai Haoyuan Chemexpress Co.,Ltd. (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.

Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1181412602"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181412602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181412602?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-12 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181412602","market":"sh","top_or_hot":-1,"title":"Drug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies","media":"Stock News","content":"<p><b>Shanghai Haoyuan Chemexpress Co.,Ltd.</b> (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.<br><br>Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrug Manufacturing Site of Shanghai Haoyuan Chemexpress Passes US FDA Inspection With Zero Deficiencies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-12 18:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shanghai Haoyuan Chemexpress Co.,Ltd.</b> (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.<br><br>Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688131","symbol_name":"皓元医药","start_time":0,"source_url":"","article_id":"1181412602","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181412602","pubTimestamp":1786530782,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Haoyuan Chemexpress Co.,Ltd. (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688131":"皓元医药","BK0216":"研究试验","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"上海浩源化学快递药品生产基地零缺陷通过美国FDA检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688131":1,"LABU":1},"content_text":"Shanghai Haoyuan Chemexpress Co.,Ltd. (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd., commonly referred to as Yaoyuan Qidong, underwent a pre-approval inspection by the United States Food and Drug Administration (FDA) from June 22, 2026, to June 26, 2026.Recently, the company received the site inspection report forwarded by Yaoyuan Qidong, officially issued by the US FDA. The report confirms that Yaoyuan Qidong successfully passed the on-site inspection with zero deficiencies. This marks the first time the company's drug formulation production base has been inspected by the US FDA, and the successful outcome provides a solid foundation for the company to further expand its presence in the American market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}